Abbott has unveiled a strategic plan to spin off its nutrition business and transform it into an independent, publicly traded company by the end of 2027. This move aims to enable the company to direct its resources entirely toward medical devices, laboratory diagnostics, and established pharmaceuticals, which are the areas with the highest growth and reliance on technical innovation.
Abbott's nutrition segment, which includes brands such as Similac, Ensure, and Pedialyte, generates approximately $8.5 billion in annual sales and recorded $2.26 billion in revenue in the third quarter, a 5% year-over-year increase. Following the completion of the spin-off, Abbott's remaining sales are expected to reach approximately $42 billion.
Background of the Decision and Legal Pressures
The announcement of the spin-off follows a series of legal and regulatory challenges faced by the nutrition segment, particularly federal investigations related to the recall of infant formula shipments in 2022. Last September, the segment announced a $385 million settlement with the U.S. Department of Justice to resolve criminal investigations and related lawsuits.
In August, the company also agreed to a separate $670 million settlement to resolve lawsuits filed by thousands of individuals regarding nutrition products for premature infants. Although some filed cases remain pending, Abbott CEO Robert Ford emphasized that the full resolution of legal disputes is not a prerequisite for completing the spin-off process.
Financial Performance and Outlook Adjustment
Concurrently with the restructuring announcement, Abbott revealed its third-quarter financial results, recording total revenue of $13.01 billion, a growth of 14.5%. However, the company lowered its sales growth forecast for 2026 to 6%, compared to its previous range of 6.5% to 7.5%.
The company explained that existing Abbott shareholders will receive shares in the new entity upon completion of the deal, which is subject to regulatory approvals. It noted that the spin-off plan will not affect the financial guidance the company will issue for 2026 and 2027 next January.
Why This News Matters
This decision reflects an increasing strategic shift among MedTech giants to divest from segments with limited growth, low margins, or complex legal liabilities, and instead focus on advanced healthcare devices and high-yield digital diagnostic tools. Abbott's move follows the path of other global companies; Medtronic has spun off its diabetes segment, while Johnson & Johnson is planning to spin off its orthopedics segment, confirming the intensifying competition in the highly innovative medical technology market.